Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,068 shares of the specialty pharmaceutical company’s stock after selling 180,141 shares during the period. Stephens Investment Management Group LLC owned approximately 3.17% of Supernus Pharmaceuticals worth $63,355,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its position in shares of Supernus Pharmaceuticals by 29.9% during the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after purchasing an additional 403,028 shares during the period. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the period. Victory Capital Management Inc. raised its position in Supernus Pharmaceuticals by 1.1% in the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after acquiring an additional 7,833 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Supernus Pharmaceuticals by 14.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after acquiring an additional 91,354 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Rice Hall James & Associates LLC now owns 540,788 shares of the specialty pharmaceutical company’s stock valued at $16,862,000 after purchasing an additional 38,202 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently weighed in on SUPN. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an “overweight” rating and a $57.00 price objective for the company. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $38.40 on Friday. The company’s 50 day simple moving average is $37.36 and its 200-day simple moving average is $34.81. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The firm has a market capitalization of $2.12 billion, a P/E ratio of 35.89 and a beta of 0.90.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.